Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03708432 | 500mg Fulvestrant in HR+ MBC | completed | — | 100 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03894410 |
| Real World Study of Lapatinib Among Metastatic Breast Cancer Patients |
| completed |
| — |
| 242 |
| Fudan UniversityOTHER |
| 1 |
| Feb 26, 2024 |
| clinicaltrials |
| NCT04001634 | Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC | completed | — | 285 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05386511 | Real-world Study of UTD1 in Chinese Advanced Breast Cancer | completed | — | 150 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05392985 | Detection and Analysis of MBC With Heterogeneous ER Expression | completed | — | 51 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05474391 | MammaPrint Value for Pre-menopausal Breast Cancer Patients | unknown | — | 200 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05572645 | Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab | completed | — | 333 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05574881 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 72 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05797987 | Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor | completed | — | 52 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05999149 | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)(BCTOP-T-N01) | recruiting | Phase 3 | 424 | Fudan UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06202404 | Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model | recruiting | — | 166 | Fudan UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05205200 | Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 | unknown | Phase 2 | 338 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05949541 | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01) | recruiting | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249308 | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) | recruiting | — | 168 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05759546 | PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | terminated | Phase 2 | 5 | Fudan UniversityOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06218810 | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06217042 | HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 3 | 524 | Fudan UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | unknown | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05954442 | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype(BCTOP-T-M03) | unknown | Phase 3 | 203 | Fudan UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06202417 | Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | completed | — | 520 | Fudan UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05446545 | Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer(EOC) | recruiting | — | 139 | Fudan UniversityOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02916511 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma(ESO-Shanghai9) | completed | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04395989 | An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.(FUTURE-SUPER) | unknown | Phase 2 | 139 | Fudan UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06177288 | DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases(DEBIRI) | unknown | N/A | 39 | Fudan UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06131645 | IASLC Grading System as a Predictor for EGFR-TKI Therapy | completed | — | 2,160 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06161935 | A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer | completed | — | 7,067 | Fudan UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06167421 | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | not yet recruiting | N/A | 240 | Fudan UniversityOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT03485027 | Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer | completed | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT05223582 | Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial | unknown | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06158919 | A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer(G/GEJ cancer) | recruiting | N/A | 58 | Fudan UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06128460 | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | not yet recruiting | Phase 2 | 24 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06151691 | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | unknown | — | 51 | Fudan UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05939063 | LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer | recruiting | N/A | 160 | Fudan UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials